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Introduction
Extra Corporeal Membrane Oxygenation (ECMO) has 
remarkably progressed over the recent years; it became 
invaluable tool in the care of adults and children with 
severe cardiac and pulmonary dysfunction refractory to 
conventional management (1,2). Nowadays ECMO has 
become more reliable with improvement in equipment, 
and increased experience, which is reflected in improving 
results. The indications are extended to more prolonged use 
in intensive care unit, such as bridge to transplant, for both 
cardiac and lung transplant and support for lung resections 
in unstable patients (3-14). According to the Extracorporeal 
Life Support Organization (ESLO) registry, ECMO was 
used in over 5,000 cases in 2014 (15), this immense increase 
of patients treated with ECMO and the vast expansion 
to its indications raises ethical questions about choosing 
what patients should be treated with ECMO, and when the 
ECMO support should be stopped (16). 
ECMO should only by performed by clinicians with 
training and experience in its initiation, maintenance, 
and discontinuation. ECMO is a supportive therapy 
rather than disease modifying treatment in itself; best 
results are obtained if we chose the right patient, the 
right type of ECMO and the right type of configuration 
(site, management and complication anticipation) (17). 
Indicat ions ,  pat ient  se lect ion,  technical  aspects , 
complications, and impact of ECMO on clinical outcomes 
will be discussed here.
Evolution of ECMO
Kolff and Berk (18) in 1944 noted that blood became 
oxygenated as it passed through the cellophane chambers 
of their artificial kidney. This concept was applied in 1953 
by Gibbon who used artificial oxygenation and perfusion 
support for the first successful open heart operation (19). 
In 1965, Rashkind and colleagues were the first to use 
a bubble oxygenator as support in a neonate dying 
of respiratory failure (20). In 1969, Dorson et al. reported 
the use of a membrane oxygenator for cardiopulmonary 
bypass in infants (21). In 1970, Baffes et al. (22) reported the 
Review Article
Extra Corporeal Membrane Oxygenation (ECMO) review of a 
lifesaving technology
George Makdisi, I-wen Wang
Indiana University School of Medicine & Indiana University Health, Indianapolis, IN 46202, USA 
Contributions: (I) Conception and design: All Authors; (II) Administrative support: IW Wang; (III) Provision of study materials or patients: All 
Authors; (IV) Collection and assembly of data: All Authors; (V) Data analysis and interpretation: All Authors; (VI) Manuscript writing: All authors; (VII) 
Final approval of manuscript: All authors
Correspondence to: I-wen Wang, MD, PhD. Indiana University School of Medicine - Division of Cardiothoracic Surgery, Indiana University Health 
Methodist Hospital, Indianapolis, IN 46202, USA. Email: IWang@iuhealth.org.
Abstract: Extra Corporeal Membrane Oxygenation (ECMO) indications and usage has strikingly 
progressed over the last 20 years; it has become essential tool in the care of adults and children with severe 
cardiac and pulmonary dysfunction refractory to conventional management. In this article we will provide 
a review of ECMO development, clinical indications, patients’ management, options and cannulations 
techniques, complications, outcomes, and the appropriate strategy of organ management while on ECMO.
Keywords: Extra Corporeal Membrane Oxygenation (ECMO); cardiogenic shock; respiratory failure; 
cardiopulmonary resuscitation
Submitted Jun 14, 2015. Accepted for publication Jun 15, 2015.
doi: 10.3978/j.issn.2072-1439.2015.07.17
View this article at: http://dx.doi.org/10.3978/j.issn.2072-1439.2015.07.17
E167Journal of Thoracic Disease, Vol 7, No 7 July 2015
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2015;7(7):E166-E176www.jthoracdis.com
successful use of extracorporeal membrane oxygenation as 
support in infants with congenital heart defects undergoing 
cardiac surgery.
Long-term ECMO as support for severe respiratory 
failure was first successfully used in 1972 in an adult patient 
with post-traumatic respiratory failure (23). Kolobow was 
developing a new membrane lung optimized for carbon 
dioxide (CO2) removal as a possible application in patients 
with chronic obstructive pulmonary disease (24). In 1975, 
Bartlett et al. reported the first successful use of ECMO in 
neonates with severe respiratory distress (25).
However, the enthusiasm decreased significantly 
when Morris et al. failed to show an outcome advantage 
of additional extracorporeal support when compared to 
conventional mechanical ventilatory support in adult 
respiratory distress syndrome (ARDS) patients in their 
randomized trial published at the beginning of the 1990s (26). 
Despite this lack of evidence, a few centers around 
Europe and in United States continued to provide veno-
venous extracorporeal support with standard mechanical 
ventilation, in selected patients, usually as a last resort with 
encouraging results (27-29).
The usage of ECMO flourish after the publication of the 
CESAR trial, which clearly showed an improvement in the 
death rate and severe disability 6 months after randomization 
of patients with severe respiratory failure treated with 
extracorporeal support in an expert high-case-volume 
center compared with no specialized hospital care (3). 
Since then the ECMO support applications exploded and 
continue to progress.
Clinical indications and contraindications for 
institution of ECMO
ECMO is a form of cardiopulmonary life-support, where 
blood is drained from the vascular system, circulated 
outside the body by a mechanical pump, and then 
reinfused into the circulation. While outside the body, 
hemoglobin becomes fully saturated with oxygen and CO2 
is removed. Oxygenation is determined by flow rate, and 
CO2 elimination can be controlled by adjusting the rate of 
countercurrent gas flow through the oxygenator (30).
Indications for ECMO can be divided into three 
categories according to the supported organ, cardiac, and 
respiratory support or a combination of the two. According 
to the data from the annual international ELSO Registry 
Reports through January 2015, over 65,171 patients 
received extracorporeal life support (ECLS) (15). The 
majority of patients were neonates 53%, 25% were pediatric 
and 23% were adults. The distribution of ECLS support 
included over 41,300 (63%) cases for respiratory support, 
over 18,700 (29%) cases for cardiac support and over 5,100 
(8%) case for extracorporeal cardiopulmonary resuscitation 
(ECPR) (15).
Indications of ECMO for cardiac support
Typical cardiac indications include refractory low cardiac 
output (cardiac index less 2 L⁄min⁄m2) and hypotension 
(systolic blood pressure <90 mmHg) despite adequate 
intravascular volume, high dose inotropic agents and an 
intra-aortic balloon pump (17). The cardiac indications are 
summarized in Table 1.
Indications of ECMO for respiratory support
Both VV ECMO and VA ECMO can be used as a rescue 
therapy in acute respiratory failure to buy time and 
Table 1 ECMO Indications for cardiac support (VA ECMO only)
o Cardiogenic shock Severe cardiac failure due to almost 
any cause:
 acute coronary syndrome
 cardiac arrhythmic storm refractory to other measures
 sepsis with profound cardiac depression
 drug overdose⁄toxicity with profound cardiac depression
 myocarditis 
 pulmonary embolism
 isolated cardiac trauma
 acute anaphylaxis
o Post cardiotomy: inability to wean from cardiopulmonary 
bypass after cardiac surgery
o Post heart transplant: primary graft failure after heart or 
heart-lung transplantation
o Chronic cardiomyopathy: 
 as a bridge to longer term VAD support
 or as a bridge to decision
o Periprocedural support for high-risk percutaneous 
cardiac interventions
o Bridge to transplant
ECMO, Extra Corporeal Membrane Oxygenation; VA, 
venoarterial.
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maintaining life awaiting improvement of the underlying 
disease. ECMO is used to provide oxygenation and CO2 
removal, or both while the lungs recover, or as a bridge to 
transplant in case of end stage lung disease. The pulmonary 
indications are shown in Table 2.
Contraindications to ECMO: the contraindications to 
ECMO are shown in Table 3.
Techniques
In VV ECMO, the patient must have stable hemodynamics. 
When single venous cannula is used, the blood is extracted 
from the vena cava or right atrium circulated and returned 
to the right atrium (Figure 1). The cannulae are usually 
placed percutaneously by Seldinger technique, via the 
right internal jugular vein. However if double venous 
cannula system is used; the cannulas are usually placed in 
the common femoral vein (for drainage) and right internal 
jugular or femoral vein (for infusion) (Figure 2).
VA ECMO provides both respiratory and hemodynamic 
support; the ECMO circuit here is connected in parallel 
to the heart and lungs, while in VV ECMO the circuit 
is connected in series to the heart and lungs. During VA 
ECMO, blood will bypass both the heart and the lungs. 
Blood is extracted from the right atrium or vena cava (for 
drainage), and returned to the arterial system either through 
peripheral cannulations via femoral, axillary or carotid 
arteries (for infusion) (Figure 3) or into the ascending 
aorta if central cannulation is used, especially in cases of 
postcardiotomy ECMO where the cannulas employed for 
cardiopulmonary bypass can be transferred from the heart 
Table 2 ECMO indications for respiratory support
o Acute respiratory distress syndrome:
 severe bacterial or viral pneumonia
 aspiration syndromes
 alveolar proteinosis
o Extracorporeal assistance to provide lung rest:
 airway obstruction
 pulmonary contusion
 smoke inhalation
o Lung transplant:
 primary graft failure after lung transplantation
 bridge to lung transplant
 intaroperative ECMO 
o Lung hyperinflation:
 status asthmaticus
o Pulmonary haemorrhage or massive haemoptysis
o Congenital diaphragmatic hernia, meconium aspiration 
ECMO, Extra Corporeal Membrane Oxygenation.
Table 3 Contraindications to ECMO
Absolute: among these futile treatment without exit strategy 
in case of
o Unrecoverable heart and not a candidate for transplant 
or destination therapy of VAD support
o Disseminated malignancy
o Known severe brain injury
o Unwitnessed cardiac arrest
o Prolonged CPR without adequate tissue perfusion
o Unrepaired aortic dissection
o Severe aortic regurgitation
o Severe chronic organ dysfunction (emphysema, 
cirrhosis, renal failure)
o Compliance (financial, cognitive, psychiatric, or social 
limitations in patient without social support)
o Peripheral vascular disease is contraindicated in 
peripheral VA ECMO 
o VV ECMO is contraindicated in cardiogenic failure 
and in Severe chronic pulmonary hypertension (mean 
pulmonary artery pressure >50 mmHg)
Relative: contraindication for anticoagulation, advanced age, 
obesity
ECMO, Extra Corporeal Membrane Oxygenation; VA, 
venoarterial.
Figure 1 Single cannula approach.
Veno-venous ECMO: double stage single cannular approach
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Figure 2 Veno-venous ECMO: two cannulation approach (A) 
femoral vein (for drainage) and right internal jugular for infusion, 
(B) both femoral veins are used for drainage and perfusion. 
ECMO, Extra Corporeal Membrane Oxygenation.   
Veno-venous ECMO: two cannulation approach
A B
Figure 3 Peripheral veno-arterial ECMO cannulation approach: femoral vein (for drainage), (A) femoral, (B) axillary, (C) carotid, artery are 
used for perfusion. ECMO, Extra Corporeal Membrane Oxygenation.
lung machine to the ECMO circuit. Blood is drained from 
the right atrium and reinfused into the ascending aorta 
(Figure 4). Comparison between VA and VV ECMO is 
shown in Table 4.
In special configuration when RVAD used as ECMO the 
oxygenated blood is delivered to the pulmonary artery so 
the blood bypass only the right heart (Figure 5). 
Femoral access is preferred for VA ECMO in case 
of emergency or cardiogenic shock because insertion is 
relatively less invasive and faster to institute the ECMO. 
The probability of an ischemia of the ipsilateral lower 
extremity can be decreased by inserting an additional 
arterial cannula distal to the femoral artery cannula 
to perfuse the distal extremity at the time of ECMO 
insertion. Alternatively, a cannula can be inserted into 
the posterior tibial artery for retrograde flow to the 
extremity (31). If the patient is in cardiac cath lab or 
ICU and is too critical to go to the operating room for 
open insertion with end to side anastomosis with graft. 
Occasionally, the femoral vessels are unsuitable for 
cannulation for VA ECMO (e.g., patients with severe 
occlusive peripheral artery disease or prior femoral 
arterial reconstruction). In such circumstances, the right 
common carotid artery should be considered as alternative 
insertion site, this technique is associated with increased 
risk of a large watershed cerebral infarction 5-10%. One 
other alternative is using of the axillary artery, which 
offers the advantage of allowing patients on ECMO to 
ambulate (32,33).
Compare indications 
The amount of oxygen provided via artificial lung is a 
directly related to the blood flow. The blood flow required 
during veno-venous approach to achieve acceptable arterial 
oxygenation is usually between 3 and 6 L/min. Arterial 
Peripheral veno-arterial ECMO cannulation approach
A B C
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oxygenation is partially dependent on the cardiac output of 
the patient (as it is connected in series with the heart), and 
the hemoglobin concentration and saturation (34). 
The veno-arterial approach implies the drainage of venous 
blood, its oxygenation and the subsequent input in the arterial 
system through a cannulated artery. The improvement of 
systemic oxygenation with this technique is much better 
as compared with the veno-venous approach because the 
artificially oxygenated blood mixes with arterial blood and 
directly perfuses distal organs. Moreover, in this type of 
cannulation the oxygenator is in parallel with the natural lung, 
comparison between VV and VA ECMO in Table 4.
Table 4 Differences between Venoarterial and Venovenous Extracorporeal Membrane Oxygenation
VA ECMO VV ECMO
Provides cardiac support to assist systemic circulation Does not provide cardiac support to assist systemic circulation
Requires arterial and venous cannulation Requires only venous cannulation
Bypasses pulmonary circulation/decreases pulmonary  
artery pressures
Maintains pulmonary blood flow
Could be used in RV failure Can’t be used
Lower perfusion rates are needed Higher perfusion rates are needed
Higher PaO2 is achieved Lower PaO2 is achieved
ECMO circuit connected in parallel to the heart and lungs ECMO circuit connected in series to the heart and lungs
ECMO, Extra Corporeal Membrane Oxygenation; VA, venoarterial; VV, venovenous. 
ECMO complications
Complications on ECMO are very common and as expected 
it is associated with significant increase in morbidity 
and mortality. These complication could be related to 
the underlining pathology needed ECMO, or of the 
ECMO condition itself (surgical insertion, circuit tubing, 
anticoagulation etc.) and as a rule of thumb, the ECMO 
inserted for pulmonary support has less complication than 
the ECMO inserted for cardiogenic support. The worst 
outcomes are reported when ECMO is used after ECPR. 
VV ECMO has fewer complications than VA ECMO, the 
children have less complications than adults except for 
neurologic complications. The most frequent complication 
during ECMO is hemorrhage, ranging between 10-30% 
(35,36). Aubron et al. reported up to 34% in VA ECMO and 
17% VV ECMO required surgery for bleeding issues (37), 
Bleeding may occur at the surgical site, at the cannula 
site, or into the site of a previous invasive procedure, 
intrathoracic, abdominal, or retroperitoneal hemorrhage 
may also occur. Bleeding is increased because of systemic 
heparinization, platelet dysfunction, and clotting factor 
hemodilution. Bleeding is managed by decreasing or 
stopping heparin and infusion of platelets and clotting 
factors (38). Infusion of activated factor VII has been 
reported with mixed results and should only be considered 
for life threatening hemorrhage after all other options have 
failed (39).
Pulmonary hemorrhage is seen commonly in patients on 
ECMO. Management includes bleeding control as above, 
using steroids, and frequent bronchoscopy to clear the 
airway over time.
Intracerebral hemorrhage or infarction occurs in 
approximately 10-15% of ARDS patients on ECMO. 
Figure 4 Central veno-arterial ECMO cannulation approach. 
ECMO, Extra Corporeal Membrane Oxygenation. 
Central veno-arterial ECMO cannulation approach
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Figure 5 Special configuration with RVAD used as ECMO. 
RVAD, right ventricle assisted device; ECMO, Extra Corporeal 
Membrane Oxygenation.
Special configuration with RVAD used as ECMO
Forty-three percent of the deaths in the ECMO (40) series 
were associated with intracranial hemorrhage.
Hemolysis does not occur during ECMO unless there 
is a problem in the circuit or the patient. Plasma free 
hemoglobin should be checked frequently; values over 
10 mg% requires further investigation in identifying and 
repairing the cause.
Systemic thromboembolism due to thrombus formation 
within the extracorporeal circuit, although it can be 
devastating, it is an infrequent complication. Its impact 
is greater with VA ECMO than VV ECMO because 
infusion is into the systemic circulation. Heparin infusion 
to achieve activated coagulation time (ACT) target, and 
vigilant observation of the circuit for signs of clot formation 
successfully prevents thromboembolism in most patients. 
Intracardiac thrombus formation (Figure 6) was also 
reported in literature (31).
Heparin-induced thrombocytopenia (HIT) can occur in 
patients receiving ECMO. When HIT is proven, heparin 
infusion should be replaced by a non-heparin anticoagulant. 
We favor using Bivalirudin in spite of Heparin even without 
HIT when anticipating long term ECMO use. Some 
authors prefer to use Argatroban because its half life is short 
and a similar ACT target range is effective (41).
Neurological complications are highly variable ranging 
between 4-37% (40,42) according to the ELSO registry (43) 
the incidence of major neurologic morbidity in cardiac 
patients as reported to ELSO is highest in neonates, 
with 7% suffering seizures, 3.5% infarction, and 11% 
intracranial hemorrhage. Children have slightly lower 
incidence of seizures and hemorrhage and a slightly higher 
incidence of infarction. Adults have the lowest incidence 
of major neurologic morbidity with 2% suffering seizures, 
4% infarction, and 2% hemorrhage. In all age groups 
those patients who suffer major neurologic complications 
have a lower hospital survival (43). In Lidegran et al. (44) 
series of 123 patients underwent ECMO a head CT scan 
was performed on 87 patients, the CT scan findings were 
Seventy-eight patients had cranial CT while on ECMO. 
Inntra cranial hemorrhage (ICH) or cerebral infarction 
was detected in 37%, 15% had focal hemorrhage, 9% 
focal infarction, and 13% general brain edema. The CT 
findings were decisive in 16 of the 45 patients to withdraw 
the ECMO treatment. It is important to realize that 
these findings may be a consequence of the condition 
that prompted ECMO, rather than a complication of the 
ECMO process (42). These may be partially due to systemic 
heparinization, thrombocytopenia, coagulopathies, or 
systolic hypertension.
Medical complications
Hypertension is a dangerous complication because of the 
risk of hemorrhage and stroke. Arrhythmias may occur 
as a result of hypoxia and electrolyte imbalance or an 
underlining cardiac pathology. Oliguria is a commonly 
observed renal complication during the early part of 
ECMO; acute tubular necrosis is observed in some patients 
and may require hemofiltration and dialysis. GI tract 
complications include hemorrhage (44), which may occur 
as a result of stress, ischemia, or bleeding tendencies. Direct 
hyperbilirubinemia and biliary calculi may occur secondary 
to prolonged fasting and total parenteral nutrition (TPN), 
hemolysis, and diuretics.
Septic complications may also result because the 
ECMO circuit represents a large intravascular foreign 
body, and frequent manipulation increases the risk of 
infection. Metabolic complications include electrolyte 
imbalances, and hypo or hyperglycemia. ECMO may alter 
serum concentration of drugs due to increased volume 
of distribution, and decreased Kidney or liver function. 
Caution is warranted when narrow therapeutic drugs are 
administered, and dose alterations may be necessary (45). 
E172 Makdisi and Wang. Extra Corporeal Membrane Oxygenation a lifesaving technology
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2015;7(7):E166-E176www.jthoracdis.com
Mechanical complications: clots in the circuit are the 
most common mechanical complication (19%). Major clots 
can cause oxygenator failure, consumption coagulopathy, 
and pulmonary or systemic emboli. More recently, heparin-
coated ECMO systems have been used to decrease the 
frequency of this complication.
VA ECMO-specific complications
Cannulation related complications: a variety of complications 
can occur during cannulation, including vessel perforation 
with hemorrhage, arterial dissection, distal ischemia, and 
incorrect location (e.g., venous cannula within the artery) 
or development of pseudoaneurysm at the site of insertion. 
These complications are rare <5%. A skilled and experienced 
surgeon is important to avoid or address such complications. 
Cardiac thrombosis (Figure 6): occurs secondary to 
retrograde blood flow in the ascending aorta whenever 
peripheral cannulation through the femoral artery and vein 
are used for VA ECMO. Stasis of the blood can occur if left 
ventricular output is not maintained, which may result in 
cardiac thrombosis.
Coronary or cerebral hypoxia: during VA ECMO, fully 
saturated blood infused peripherally into the femoral artery 
from the ECMO circuit will preferentially perfuse the 
lower extremities and the abdominal viscera. Blood ejected 
from the heart will selectively perfuse the heart, brain, 
and upper extremities. As a result, cardiac and cerebral 
hypoxia could exist and be unrecognized if oxygenation is 
monitored using only blood from the lower extremity. To 
avoid this complication, arterial oxyhemoglobin saturation 
should be monitored in both the upper extremity and the 
lower extremity. Poor arterial oxyhemoglobin saturations 
measured from the upper extremity is corrected by infusing 
some oxygenated blood into the right atrium.
Organ management in ECMO patient
Organ management is very critical in obtaining good 
survival outcomes with better quality of life, better general 
health, physical health, and social functioning. The aim 
of organ management is to avoid multiorgan failure in 
a patient who is suffering primary of the failure of the 
heart, lung or both; before initiating the ECMO, better 
understanding to the new hemodynamics and physiologic 
body response to the ECMO circuit and hemodynamics 
play a major role in outcomes.
Cardiovascular system management: systemic perfusion 
and intravascular volume should be maintained. Volume 
status can be assessed clinically by urine output, central 
venous pressure, physical signs of perfusion, and body 
weight. Good cardiac output should be achieved with 
inotropic agents. Echocardiography should be performed 
to assess the heart’s condition, and heart recovery, rule 
out thrombosis, and should be repeated if any significant 
changes in the ECMO flow, or deterioration in the patient’s 
hemodynamics.
Pulmonary system management: ECMO is used 
temporarily while awaiting lung recovery. In some 
centers, a high PEEP has been used to avoid atelectasis. 
Pulmonary hygiene is strict and requires frequent positional 
changes, endotracheal suctioning every 4 hours depending 
on secretions, a daily chest radiograph, and flexible 
bronchoscopy when needed.
Renal system management: during the first 24-48 hours 
ECMO patients experience an oliguric phase as the ECMO 
circuit triggers an acute inflammatory reaction. This 
leads to capillary leak and intravascular volume depletion 
resulting in oliguria and acute tubular necrosis. After 
48 hours the diuretic phase begins (which is one of the earliest 
signs of recovery). If oliguria persists for 48-72 hours, diuretics 
are often required to reduce edema. When renal failure 
does not improve, continuous renal replacement therapy 
(CRRT) may be added to the circuit. Kielstein et al. (46) 
demonstrated that 60% of ECMO patients required CRRT 
for acute renal injury (AKI), the 3-month survival of ECMO 
patients requiring CRRT for AKI was 17% vs. 53% without 
CRRT. They concluded that AKI requiring CRRT in 
Figure 6 LV thrombus in 19 years old patient with idiopathic 
cardiomyopathy and LVEF 10%, a thrombus developed after 
central VA ECMO. LV, left ventricle; LVEF, left ventricle ejection 
fraction; ECMO, Extra Corporeal Membrane Oxygenation; VA, 
venoarterial.
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patients undergoing ECMO treatment increases mortality 
and the longer duration of CRRT was also associated with 
a higher mortality. Zwiers et al. (47) showed that neonates 
who suffer AKI in association with ECMO are at increased 
risk for developing chronic kidney disease (CKD) and/or 
hypertension in median of 8.2 years of follow-up.
Central nervous system (CNS) managements: CNS 
complications are very common; it was reported in up to 
48% of patients who received ECMO for greater than 12 
hours (3). These complications are related to the degree 
of hypoxia and acidosis or primarily as consequence 
of the condition that prompted ECMO, rather than a 
complication of the ECMO process. Avoiding paralytic 
agents and performing regular sedation vacation and 
neurologic examinations are recommended. Imaging studies 
though difficult to obtain in unstable patients should be 
used in case of suspicion (44). In patients with seizures or 
suspected seizures, aggressive treatment is recommended.
Infection control: strict aseptic precautions are required (13). 
The presence of infection is monitored by obtaining 
cultures from the circuit at least once a week or when 
infection is suspected. Based on institutional experience, the 
protocol frequency may vary.
Hematologic considerations: to optimize oxygen delivery, 
the patient’s hemoglobin should be maintained at higher 
than 8 g/dL. As a result of platelet consumption during 
ECMO, platelet transfusions are required to maintain 
platelet counts above 100,000/mcL. Activated clotting time 
(ACT) should be maintained at 180-240 seconds to avoid 
bleeding complications (48).
We favor using direct thrombin inhibitors like Bivalirudin 
in spite of Heparin when anticipating long term ECMO use as, 
LVAD or transplant candidates. Bivalirudin dose adjustments 
are needed to maintain APTT 1.5-2.5 times baseline values or 
within the physician-defined range (49). Some authors prefer 
to use Argatroban because its half life is shorter than heparin 
and a similar ACT target range is effective.
Fluids, Electrolytes and Nutrition: patients on ECMO 
require close monitoring of fluids and electrolytes (potassium, 
magnesium, phosphorus and ionized calcium). The high-
energy requirements should be met using hyperalimentation 
techniques. The patient’s weight increases in the first 1-3 days 
on ECMO because of the need of fluid resuscitation, fluid 
retention, and oliguric phase.
Outcomes
According to the data from the annual international ELSO 
Registry Reports through January 2015 (15), 65,171 patients 
received ECLS, among these, 71% were weaned and 
59% were discharged or transferred. Use of ECLS for 
respiratory support represents a large area of consistent 
growth. Over 141,300 patients have been treated with 
survival to discharge rates of 74%, 57%, and 57% for 
neonates, pediatric, and adults, respectively. Use of ECLS 
for cardiac support also represents a large area of consistent 
growth. Approximately 18,800 patients have been treated 
ECLS with survival to discharge rates of 41%, 50%, and 
41% for neonates, pediatric, and adults, respectively (15).
The survival of patients undergoing ECMO can be 
categorized according to the indication for the ECMO: 
severe acute respiratory failure or cardiac failure.
Acute respiratory distress syndrome (ARDS): Hemmila 
et al. (36) showed that 67% of patients with acute respiratory 
failure treated with ECMO were weaned off ECMO and 
52% survived to hospital discharge. This was also confirmed 
by the CESAR study (3) which demonstrated that referral 
to an ECMO center significantly improves recovery and 
survival from severe ARDS. Therefore, we recommend that 
adult patients with severe ARDS be referred to an ECMO 
center. In experienced ECMO centers, approximately 25% of 
patients will improve and recover without ECMO, while 75% 
of patients will require ECMO. Among those who require 
ECMO, 60% to 70% will survive. The group referred 
to the ECMO center had significantly increased survival 
without disability at six months compared to conventional 
management (63% vs. 47%). Similar conclusions were 
obtained regarding referral and transfer patients with severe 
influenza H1N1-related acute respiratory distress syndrome 
to an ECMO center, this was associated with lower hospital 
mortality (23.7% vs. 52.5%) (50).
Venoarterial (VA) ECMO can provide acute support in 
cardiogenic shock or cardiac arrest in adults. Assuming that 
the brain function is normal or only minimally impaired, 
ECMO is provided until the patient recovers or receives 
a long-term ventricular assist device as a bridge to cardiac 
transplantation. Survival rate reported in the literature 
range between 20-30% among patients who received VA 
ECMO for cardiac arrest, severe cardiogenic shock, or 
failure to wean from cardiopulmonary bypass following 
cardiac surgery (13,51,52). Shin et al. (53) demonstrated 
that ECMO performed for cardiac arrest was associated 
with increased survival with minimal neurologic impairment 
compared to conventional cardiopulmonary resuscitation, 
these findings were confirmed by Chen et al. at discharge 
time, 30 days, and 1 year survival (54).
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Safeguard and tips for safe technique
VV ECMO: the perfect position when using one venous 
cannula is when the distal tip of the cannula lying below the 
diaphragm (in the IVC) with the proximal opening in the 
SVC or SVC/right atrium junction, orienting the opening 
of the arterial cannula toward the tricuspid valve (Figure 1). 
Check cannula position regularly and on a daily basis, and 
during acute events in such as significant drop in ECMO 
flow, or in blood saturation. Immigration into the right 
ventricle or into the coronary sinus should be ruled out. 
And when signs of right ventricle dysfunction manifest we 
should consider switching to VA ECMO.
Peripheral VA ECMO: should be avoided in a patient 
with a history of peripheral vascular disease, if Seldinger 
technique is used; avoid to put the arterial and venous 
cannula in the same groin side, to avoid venous congestion 
from the collapsed femoral vein laminated by the adjacent 
arterial cannula, insert only the tip of the arterial cannula, 
the best way to avoid distal ischemia is to insert the arterial 
cannula on end to side graft (the cannula is not in the artery 
lumen), don’t wait for compartment syndrome signs to 
develop, to perform faschiotomy. Be aware of the risk of 
left ventricle dysfunction and distension in case of low LV 
function because of poorly contracting, non-ejecting left 
ventricle or atrium as little blood reaches the left atrium with 
good right atrial drainage, switch the peripheral cannulation 
to central with LV vent, keep the patient on inotropic drugs 
such as Epinephrine, Dobutamine or Norepinephrine, 
adding peripheral impella, or percutaneous atrial septostomy 
represent alternative options (55,56).
In case of central VA ECMO in case of a patient with 
LV dysfunction; add LV vent to the circuit and proceed as 
mentioned earlier, insert the cannulas in separate incision 
of the surgical incision to temporarily close the chest this 
technique will help patient to resume ambulation.
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